#108

Strut Health Review

Item: Strut Health
Rating: 3.85
Author: Rx Saver Hub

Oral and injectable compounded GLP-1s, with the FDA caveat stated up front

7.7/10

Good

7.7/10

Not published — pricing shown after intake

Visit Site

FDA action on record

FDA reviewed struthealth.com and stated that claims concerning the compounded GLP-1 products offered there were false or misleading.

Entity: Strut Health, LLC dba Strut
Action: FDA warning letter (MARCS-CMS 721448)
Date: February 20, 2026

A warning letter is FDA's stated position that violations occurred. It is not a court finding, a recall, or a determination that any patient was harmed, and these letters concerned marketing claims about compounded GLP-1 products rather than a specific batch of medication. Companies often respond and correct the cited material. We publish this so you can weigh it yourself — read the letter and check the provider's current status before deciding.

Read the FDA letter on fda.gov →

Overview

Strut Health is a broad telehealth service — dermatology, hair loss, sexual health and weight loss — whose GLP-1 line is unusual for offering both daily oral and weekly injectable compounded options, including an oral tirzepatide tablet. What it does well is disclosure of a specific kind: the weight loss page carries the compounded caveat directly beneath each product, stating that compounded drug products are not approved or evaluated for safety, effectiveness or quality by the FDA and that a prescription is required. Many competitors bury that in a footer. Two things temper it. Strut does not publish GLP-1 pricing on the page we reviewed, so cost is only visible after intake. And FDA issued Strut Health, LLC a warning letter dated February 20, 2026 (MARCS-CMS 721448) after reviewing struthealth.com — the notice and link appear on this page.

Pros

Both daily oral tablets and weekly injectable compounded GLP-1s
Offers an oral tirzepatide option, which is uncommon
States the compounded FDA caveat directly under each product rather than in a footer
Provider-supervised programmes rather than prescription-only
Broad catalogue — dermatology, hair, sexual health — under one account

Cons

FDA warning letter dated February 20, 2026 over claims on its website
GLP-1 pricing is not published — visible only after intake
Compounding pharmacy is not named
No published state availability list
Compounded medications are not FDA-approved as finished products

Key Features

Oral Semaglutide (Compounded)

Oral Tirzepatide (Compounded)

Injectable Compounded GLP-1

Provider-Supervised Programmes

Multi-Category Telehealth

Best For

Patients who specifically want an oral compounded GLP-1 tablet rather than an injection

Strut Health at a Glance

Everything below reflects what Strut Health published on its own site as of August 24, 2026. Where a detail is not published, we say so rather than guessing.

Medications offered

• Oral compounded semaglutide
• Oral compounded tirzepatide
• Injectable compounded semaglutide
• Dermatology, hair loss and sexual health treatments

Brand-name or compounded

Compounded. Strut states directly on its weight loss page that compounded drug products are not approved or evaluated for safety, effectiveness or quality by the FDA, and that a prescription is required.

Consultation process

Online intake reviewed by a provider, with programmes described as provider-supervised. Pricing becomes visible during the intake flow rather than being published up front.

Eligibility